Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 17 chart positions in 17 markets.
By chart position
- 🇺🇸US · Medicine#1755K to 30K
- 🇮🇳IN · Medicine#5710K to 30K
- 🇰🇷KR · Medicine#1571K to 10K
- 🇯🇵JP · Medicine#1931K to 10K
- 🇵🇭PH · Medicine#2410K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
19K to 69K🎙 Daily cadence·191 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
63K to 229K🇺🇸13%🇮🇳13%🇵🇭13%+14 more - Active Followers
Loyal subscribers who consistently listen
25K to 92K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 15 epsHosts
Recent guests
Recent episodes
ASCO 2026 Plenary: SARC-041
Jun 22, 2026
11m 34s
ASCO Annual Meeting 2026 GU Recap
Jun 15, 2026
14m 41s
ASCO 2026 Plenary: RASolute-302
Jun 8, 2026
11m 26s
ASCO Annual Meeting 2026 Preview
May 25, 2026
11m 26s
Von Willebrand Disease (VWD) 2026 UPDATE
May 18, 2026
13m 15s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/22/26 | ASCO 2026 Plenary: SARC-041 | This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo. | 11m 34s | ||||||
| 6/15/26 | ASCO Annual Meeting 2026 GU Recap | Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer. | 14m 41s | ||||||
| 6/8/26 | ASCO 2026 Plenary: RASolute-302✨ | ASCO PlenaryRASolute 302 trial+4 | — | daraxonrasibRASolute 302 trial+1 | metastatic pancreatic ductal adenocarcinoma | ASCO 2026RASolute 302+4 | — | 11m 26s | |
| 5/25/26 | ASCO Annual Meeting 2026 Preview✨ | ASCO Annual MeetingGU sessions+3 | — | ASCO | Chicago | ASCOAnnual Meeting+5 | — | 11m 26s | |
| 5/18/26 | Von Willebrand Disease (VWD) 2026 UPDATE✨ | Von Willebrand diseasebleeding disorders+3 | — | bleeding disorderVon Willebrand disease (VWD) | — | Von Willebrand diseaseVWD+5 | — | 13m 15s | |
| 5/11/26 | Aplastic Anemia 2026 UPDATE✨ | Aplastic Anemiadiagnostic work-up+3 | — | Aplastic AnemiaPNH | — | Aplastic Anemiadiagnosis+5 | — | 11m 30s | |
| 5/4/26 | Metastatic Bladder Cancer 2026 UPDATE✨ | metastatic bladder cancertreatment options+4 | — | urothelial carcinoma | — | metastatic bladder cancertreatment options+4 | — | 9m 20s | |
| 4/27/26 | Localized Bladder Cancer 2026 UPDATE✨ | bladder cancerpathology+3 | — | localized bladder cancer | 2026 | bladder cancerlocalized cancer+5 | — | 13m 21s | |
| 4/20/26 | 4 Years with Two Onc Docs✨ | anniversarypodcast future+3 | — | Two Onc DocsBladder Cancer | — | Two Onc Docshematology+3 | — | 12m 00s | |
| 4/13/26 | Pancreatic Cancer x Dr. Michael Pishvaian 2026 UPDATE Part 3✨ | pancreatic cancersupportive care+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | pancreatic cancersupportive care+3 | — | 14m 01s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/6/26 | Metastatic Pancreatic Cancer x Dr. Michael Pishvaian 2026 UPDATE Part 2✨ | metastatic pancreatic cancer1L treatments+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | metastatic pancreatic cancer1L treatments+3 | — | 25m 07s | |
| 3/30/26 | Localized Pancreatic Cancer x Dr. Michael Pishvaian 2026 UPDATE Part 1✨ | Pancreatic Cancerrisk factors+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | localized pancreatic cancerrisk factors+3 | — | 37m 00s | |
| 3/23/26 | ASCO GU 2026 Takeaways✨ | ASCO GUprostate cancer+3 | — | ASCO GU | San Francisco | ASCO GUprostate cancer+5 | — | 12m 09s | |
| 3/16/26 | Neuroendocrine Tumors 2026 UPDATE✨ | Neuroendocrine Tumorsdiagnosis+3 | — | Neuroendocrine Tumorsgastro-entero-pancreatic NETs | — | Neuroendocrine TumorsNET+3 | — | 23m 35s | |
| 3/9/26 | Venous Thromboembolism (VTE) in Cancer Part 2✨ | Venous ThromboembolismCancer+5 | Dr. Marc Carrier | — | — | VTEcancer+6 | — | 14m 24s | |
| 3/2/26 | Venous Thromboembolism (VTE) in Cancer Part 1✨ | Venous ThromboembolismCancer+3 | Dr. Marc Carrier | University of Ottawa | — | VTEcancer+3 | — | 12m 05s | |
| 2/24/26 | ASCO GU 2026 Preview✨ | ASCO GUcancer research+4 | — | ASCOprostate cancer+3 | San Francisco | ASCO GUcancer+6 | — | 11m 35s | |
| 2/16/26 | Rad Onc 101 Part 2 | This week’s episode, we are back with our special guest Dr. Ria Kraft, a radiation oncologist and host of Rad Onc Talks. In part 2, we go over important details on duration + fractionation schemes, indications for palliative RT, other indications for RT in metastatic disease, and more. | 16m 04s | ||||||
| 2/9/26 | Rad Onc 101 Part 1 | This week’s episode will be focusing on basics of radiation oncology. We are so excited to welcome a special guest Dr. Ria Kraft, who has a YouTube channel called Rad Onc Talks for radiation oncology education. In part 1, we go over important details on types of radiation, how it works, the patient experience, common side effects and more. | 18m 11s | ||||||
| 2/3/26 | Career Pathways in Heme/Onc with Special Guest Dr. Chadi Nabhan | This week’s episode we are so excited to welcome Dr. Chadi Nabhan, who is a hematologist and medical oncologist, author, and host of Healthcare Unfiltered. We discuss why oncology, our career paths, different career paths in hematology and oncology, contract & negotiation considerations, as well as tips to search for a job. | 34m 39s | ||||||
| 1/19/26 | Oncology Nutrition 101 Part 2 | This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition. In part 2, we will go over dietary strategies focusing on cancer prevention, and myths around what causes cancer. | 15m 45s | ||||||
| 1/12/26 | Oncology Nutrition 101 Part 1 | This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition. In part 1, we will go over information + myths in oncology nutrition including cancer feeds sugar, fiber, estrogen, supplements, fasting, and more. | 26m 49s | ||||||
| 1/5/26 | Follicular Lymphoma 2026 UPDATE | Happy New Year! This week’s episode will be focusing on 2026 update for Follicular Lymphoma. We will go over the important details on the diagnostic criteria, indications for treatment and types + toxicities of treatment. | 13m 23s | ||||||
| 12/16/25 | ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL | This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL). | 11m 00s | ||||||
| 12/8/25 | Gastrointestinal Stromal Tumor (GIST) 2025 UPDATE | This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST with a 2025 update. We will go over important details on the diagnosis, mutations, and treatment of local and metastatic GISTs. | 17m 57s | ||||||
Showing 25 of 200
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
18 placements across 17 markets.
Chart Positions
18 placements across 17 markets.